Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2-5 and MAXIMISE studies.
Renaud FeltenLaura WidawskiLionel SpielmannCorine GaillezWeibin BaoJacques-Eric GottenbergPierre-Marie DuretLaurent MesserPublished in: RMD open (2023)
Patients with PsA and hyperuricaemia have different clinical characteristics from patients with PsA and normouricaemia. Identification of these patients at an early stage may facilitate a personalised treatment approach and improved management of comorbidities. Furthermore, secukinumab provided a rapid and sustained response across all manifestations of PsA up to week 52, irrespective of baseline uricaemia status.
Keyphrases
- prostate cancer
- early stage
- radical prostatectomy
- ankylosing spondylitis
- rheumatoid arthritis
- current status
- randomized controlled trial
- squamous cell carcinoma
- sentinel lymph node
- combination therapy
- case control
- radiation therapy
- systemic lupus erythematosus
- lymph node
- neoadjuvant chemotherapy
- bioinformatics analysis
- replacement therapy
- study protocol
- locally advanced